Jeremie Calais, MD, MSc, presented “PET Imaging for Selection of Focal Therapy Candidates​” during the 2022 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on September 23, 2022, in Los Angeles, California.

How to cite: Calais, Jeremie. “PET Imaging for Selection of Focal Therapy Candidates.” September 23, 2022. Accessed Jul 2024.

PET Imaging for Selection of Focal Therapy Candidates – Summary

Jeremie Calais, MD, MSc, Associate Professor of Nuclear Medicine and Theranostics in the Department of Molecular and Medical Pharmacology at UCLA, discusses PSMA, or Prostate Specific Membrane Antigen. He explains that PSMA PET imaging is a game-changing prostate cancer imaging biological target that can create imaging of prostate cancer cells. The level of overexpression is 100 to 1000 times higher than normal levels. Recent 2018, 2019, and 2020 studies, along with many others, have proven that PSMA PET is more sensitive and specific than other imaging modalities at detecting and localizing prostate cancer at the whole body level. He explains that its key strength is to detect nodal and distant metastatic disease, which allows physicians to detect earlier and more accurate disease staging. Dr. Calais continues to state that the research PSMA injection Gallium GA 68 PSMA-11 was approved in December 2020. Other commercial options followed, such as Piflufolastat F 18 and PSMA 11 in 2021. Studies have shown PSMA PET to be helpful for upstaging disease at more advanced stages such as T2c, T3a, and T3b. Dr. Calais states that when the PSMA PET signal is higher, it indicates a more aggressive disease. MRI and PSMA PET together can give a more comprehensive vision of prostate cancer cells within and outside of the prostate. There are success stories of PSMA PET results defining targeting information where an MRI-guided biopsy failed. He concludes by reviewing case studies of PSMA PET with cryotherapy or HIFU.

The annual symposium on Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies. For more educational activities from the symposium that took place from September 23-24, 2022 in Los Angeles, California, visit our collection page.


Dr Jérémie Calais, MD, PhD, is an Associate Professor of Nuclear Medicine and Theranostics in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). He is the director of the UCLA Theranostics Program and the Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division. Dr. Calais earned his medical degree and Master of Science degree at the University of Paris in France.
Dr. Calais is a nuclear medicine physician specializing in cancer imaging and theranostics. He conducts investigator-initiated and industry-sponsored clinical trials of targeted molecular imaging and therapy. His goal is to improve the outcome of patients with cancer through theranostic approaches and the application of knowledge gained from preclinical models and clinical studies.